NCT06957223

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Asad Ullah Jan · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.

Conditions

• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Dextromethorphan-Bupropion	Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.
DRUG	SSRIs	Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.

Timeline

• Start date: 2025-05-06
• Primary completion: 2025-11-30
• Completion: 2025-12-31
• First posted: 2025-05-04
• Last updated: 2025-07-09

Locations

2 sites across 1 country: Pakistan